NASDAQ · LIMN
Liminatus Pharma, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for LIMN: Nov 12, 2026
Liminatus Pharma, Inc. Class A Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. The reported EPS for the same quarter last year was $-3.5.
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · NASDAQ.com · Quiver Quantitative- RTTNews · Sep 30, 5:14 AM EDTLiminatus Pharma Regains Nasdaq Compliance Following 1-For-50 Reverse Split(RTTNews) – Liminatus Pharma, Inc. (LIMN), a biotechnology company developing immuno-oncology and cell therapy candidates, announced that it has regained compliance with Nasdaq's minimum bid price rule.
- RTTNews · Aug 19, 3:02 AM EDTLiminatus Pharma Announces 1-for-50 Reverse Stock Split; Stock Down(RTTNews) – Liminatus Pharma, Inc. (LIMN) announced that its board of directors has approved a reverse stock split of its common stock, par value $0.0001 per share, at a ratio of 1-for-50.
- RTTNews · Aug 13, 8:46 AM EDTLiminatus Pharma Transfers To Nasdaq Capital Market; Shares Surge In Pre-Market(RTTNews) – Liminatus Pharma, Inc. (LIMN), a biopharmaceutical company developing novel cancer therapies, announced that its common stock has been transferred from the Nasdaq Global Market to the Nasdaq Capital Market, effective August 4, 2026.
- RTTNews · Jul 1, 3:06 AM EDTLiminatus Pharma Amends Merger Agreement With InnocsAI To Expand Oncology Pipeline(RTTNews) – Liminatus Pharma, Inc. (LIMN), a biotechnology company developing cancer therapies, announced it has amended and restated its definitive merger agreement with InnocsAI LLC, an oncology biotech focused on next-generation cell therapy technologies.
- RTTNews · Jun 4, 5:07 AM EDTLiminatus Pharma Enters Into $1.9 Mln Warrant Exercise Transaction(RTTNews) – Liminatus Pharma, Inc. (LIMN), a biopharmaceutical company, announced that it has entered into a warrant exercise agreement with existing accredited investors to exercise certain outstanding warrants to purchase an aggregate of 10.34 million shares.
- RTTNews · Feb 17, 9:52 AM ESTLiminatus Pharma Prices $4 Mln Offering Of Shares And Warrants; Stock Down(RTTNews) – Liminatus Pharma, Inc. (LIMN), a pre-clinical stage immuno-oncology company, announced the pricing of 13.81 million shares and warrants to purchase up to 20.72 million shares at a combined public offering price of $0.29 per share or $0.29 per pre-funded warrant.
- NASDAQ.com · Aug 22, 8:29 AM EDTPre-Market Most Active for Aug 22, 2025 : LIMN, LCID, INTC, SQQQ, TSLL, OPENThe NASDAQ 100 Pre-Market Indicator is up 22.63 to 23,165.21. The total Pre-Market volume is currently 260,128,110 shares traded.The following are the most active stocks for the pre-market session: Liminatus Pharma, Inc. (LIMN) is +1.02 at $3.80, with 20,037,536 shares traded.,
- NASDAQ.com · Jul 24, 8:29 AM EDTPre-Market Most Active for Jul 24, 2025 : TSLL, OPEN, LIMN, AAL, TSLA, TSLQ, NIO, CIO, PCG, CMG, AEO, DOWThe NASDAQ 100 Pre-Market Indicator is up 52.92 to 23,215.33. The total Pre-Market volume is currently 138,722,697 shares traded.The following are the most active stocks for the pre-market session: Direxion Daily TSLA Bull 2X Shares (TSLL) is -1.56 at $11.10, with 27,380,722 sha
- Quiver Quantitative · Jul 22, 1:40 PM EDTLiminatus Pharma Initiates Strategic Review of Regulated Digital Asset Strategies for Treasury ManagementLiminatus Pharma is exploring regulated digital asset strategies to enhance treasury management while focusing on cancer immunotherapy development.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Liminatus Pharma, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.